TScan Therapeutics, Inc.
TCRXNasdaq
$0.91
↑ +1.8%Jul 17 close · end-of-day
Price
1Y↓ -49.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$118.8M
Enterprise Value
$23.4M
P/E
—
P/S
13.0
P/B
1.2
EV/EBITDA
—
PEG
—
FCF Yield
-105.1%
Dividend Yield
—
Revenue (TTM)
$9.1M
Net Income (TTM)
-$124.3M
Free Cash Flow (TTM)
-$125.0M
Gross Margin
—
Operating Margin
-1408.7%
Net Margin
-1360.6%
ROE
-128.3%
ROIC
-6693.5%
Debt / Equity
0.3
Net Cash
$95.4M
Return 1Y
-51.6%
Company profile
TScan Therapeutics, Inc. develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2.
- CEO
- David P. Southwell
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- Massachusetts
- Website
- tscan.com
Earnings
TCRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$982,000.00↓ -54.8%
Diluted EPS-$0.22↓ -15.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.1M | $10.1M | $13.5M | $21.0M | $2.8M | $10.3M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$26.2M | -$48.6M | -$66.6M | -$93.5M | -$134.8M | -$135.8M |
| Net income | -$26.1M | -$48.6M | -$66.2M | -$89.2M | -$127.5M | -$129.8M |
| Diluted EPS | — | -$4.17 | -$2.75 | -$1.36 | -$1.14 | -$1.00 |
| Operating cash flow | -$3.0M | -$48.7M | -$66.5M | -$61.4M | -$110.8M | -$135.3M |
| Free cash flow | -$7.3M | -$58.6M | -$70.7M | -$64.5M | -$114.6M | -$139.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -2417.8% | -479.6% | -492.3% | -444.0% | -4787.7% | -1315.4% |
| Net margin | -2408.0% | -479.5% | -489.3% | -423.9% | -4527.7% | -1256.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $536,000.00 | $1.0M | $665,000.00 | $2.2M | $3.1M | $2.5M | $2.6M | $982,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$34.1M | -$32.6M | -$36.7M | -$36.3M | -$38.7M | -$37.1M | -$23.9M | -$29.1M |
| Net income | -$31.7M | -$29.9M | -$35.8M | -$34.1M | -$37.0M | -$35.7M | -$23.0M | -$28.7M |
| Diluted EPS | -$0.28 | -$0.25 | -$0.29 | -$0.26 | -$0.28 | -$0.28 | -$0.18 | -$0.22 |
| Operating cash flow | -$26.2M | -$27.9M | -$27.4M | -$37.6M | -$33.3M | -$32.5M | -$32.0M | -$24.3M |
| Free cash flow | -$27.1M | -$29.3M | -$28.3M | -$39.1M | -$34.5M | -$33.9M | -$32.2M | -$24.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -6364.6% | -3109.8% | -5520.6% | -1669.7% | -1256.6% | -1475.6% | -929.4% | -2967.3% |
| Net margin | -5906.9% | -2849.1% | -5384.8% | -1571.9% | -1201.3% | -1422.1% | -895.1% | -2919.1% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-12-23 | Lynx1 Capital Management LP | Buy | 6,232 | $0.90 | $5,601.94 | filing |
| 2025-12-22 | Lynx1 Capital Management LP | Buy | 75,500 | $0.90 | $67,950.00 | filing |
| 2025-12-19 | Lynx1 Capital Management LP | Buy | 80,069 | $0.90 | $71,974.02 | filing |
Latest 3 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.